LifeArc Ventures — 2026 Investments

2 investments dated 2026 · listed companies and verified rows first · show all

Droia Venturesdroiaventures.comJan 2026

Droia Ventures is a specialist venture capital firm investing globally in early-stage drug development companies focused on therapeutics for oncology and genetic disease.

BiotechLeuven, BE

Co-investorsClavystBio Frazier Life Sciences Novo Holdings

RQ Biorqbiotechnology.comJun 2026 · $115M

RQ Bio discovers and develops long-acting monoclonal antibodies (LAAbs) targeting seasonal influenza to provide protection against severe viral disease.

BiotechHealthtech

Co-investorsFrazier Life Sciences Oxford Science Enterprises Wellington Management EQT Life Sciences Forbion Monograph Capital Partners +1 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.